Home/Filings/3/0001213900-19-004601
3//SEC Filing

Bioengine Capital Inc. 3

Accession 0001213900-19-004601

CIK 0000946486other

Filed

Mar 20, 8:00 PM ET

Accepted

Mar 21, 12:17 PM ET

Size

8.5 KB

Accession

0001213900-19-004601

Insider Transaction Report

Form 3
Period: 2018-12-21
Holdings
  • SERIES F WARRANTS

    Exercise: $3.68From: 2018-12-24Exp: 2020-06-24COMMON STOCK (384,824 underlying)
  • COMMON STOCK

    3,551,750
  • SERIES G WARRANTS

    Exercise: $4.05From: 2018-12-24Exp: 2023-12-24COMMON STOCK (747,012 underlying)
Holdings
  • COMMON STOCK

    3,551,750
  • SERIES G WARRANTS

    Exercise: $4.05From: 2018-12-24Exp: 2023-12-24COMMON STOCK (747,012 underlying)
  • SERIES F WARRANTS

    Exercise: $3.68From: 2018-12-24Exp: 2020-06-24COMMON STOCK (384,824 underlying)
Footnotes (3)
  • [F1]The shares are directly held by Bioengine Capital Inc. and indirectly held by Center Laboratories, Inc., which owns 58.6% of Bioengine Capital Inc.
  • [F2]The exercisable shares of Series F Warrants will be directly held by Bioengine Capital Inc. and indirectly held by Center Laboratories, Inc.
  • [F3]The exercisable shares of Series G Warrants will be directly held by Bioengine Capital Inc. and indirectly held by Center Laboratories, Inc.

Documents

1 file

Issuer

WINDTREE THERAPEUTICS INC /DE/

CIK 0000946486

Entity typeother
IncorporatedTaiwan, Province of China

Related Parties

1
  • filerCIK 0001770197

Filing Metadata

Form type
3
Filed
Mar 20, 8:00 PM ET
Accepted
Mar 21, 12:17 PM ET
Size
8.5 KB